Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200485 · ClinicalTrials.gov registry record · Phase 2
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT01200485: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01200485 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01200485, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if using Elitek (rasburicase) for 2 cycles can help to control or prevent TLS better than 1 cycle of rasburicase and 1 cycle of allopurinol. The safety of this treatment will also be studied.
Interventions
- DRUG Allopurinol
- DRUG Rasburicase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2011-04 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01200485
The ClinicalTrials.gov registry entry for NCT01200485 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allopurinol is the first listed.
NCT01200485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01200485 about?
NCT01200485 is a clinical study titled "Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2". The goal of this clinical research study is to learn if using Elitek (rasburicase) for 2 cycles can help to control or prevent TLS better than 1 cycle of rasburicase and 1 cycle of allopurinol. The safety of this treatment will also be studied.
What is the current status of trial NCT01200485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2011-04. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01200485?
The interventions under investigation include: Allopurinol (DRUG), Rasburicase (DRUG).
Who is sponsoring clinical trial NCT01200485?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.